Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...
The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.
Moby Strategic Execution and Operational Pivot. Achieved a significant financial turning point in 2025 by reducing operating expenses ...
In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.